Viewpoint Molecular Targeting sets sights on growth in 2021

March 8, 2021

Viewpoint Molecular Targeting, an Iowa JPEC Faculty Innovators alumnus, is starting 2021 with momentum. Over the last 6 months, the company accrued $18 million in funding, secured its own supply chain of radioisotopes, unveiled positive preclinical data; and secured its first investigational new drug application by the US FDA in the lead up to their first human trials at the Mayo Clinic and the University of Iowa.